Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.

CONCLUSION: RD-plerixafor is an effective, safe, and affordable strategy to ensure adequate PBSC mobilization in patients with MM or lymphoma who undergo ASCT.
PMID: 31618456 [PubMed - as supplied by publisher]

Source: Transfusion - October 15, 2019 Category: Hematology Authors: Gutiérrez-Aguirre CH, Alvarado-Navarro DM, Palomares-Leal A, Mejía-Jaramillo G, Salazar-Riojas R, León AG, Colunga-Pedraza PR, Sotomayor-Duque G, Jaime-Pérez JC, Cantú-Rodríguez OG, Del Carmen Tarín-Arzaga L, Flores-Jiménez JA, Gómez-Almaguer D Tags: Transfusion Source Type: research